News | Thrombectomy Devices | January 16, 2019

Cerenovus Launches Global Registry for EmboTrap II Revascularization Device

Company also receives European CE Mark approval for novel stroke technology designed for difficult-to-extract blood clots

Cerenovus Launches Global Registry for EmboTrap II Revascularization Device

January 16, 2019 — Cerenovus, of Johnson & Johnson Medical Devices Companies, recently launched the EXCELLENT Registry to collect and analyze stroke-inducing blood clots removed from the brain with its Embotrap II Revascularization Device. The company also announced European CE Mark approval for the Geometric Clot Extractor (GCE) Revascularization Device.

The EXCELLENT Registry, which the company calls the single largest global registry of its kind, will enroll up to 1,000 ischemic stroke patients in as many as 50 clinical sites in the United States and Europe. Real-world evidence will be collected on all patients, and clots will be preserved and studied to determine how different clot characteristics — including size, composition and density — may impact or relate to patient comorbidities, clinical outcomes and revascularization rates.

Extensive clot research conducted by Cerenovus was the basis for the development of the Embotrap II Device, a next-generation stent retriever that features a dual-layer design that allows doctors to maintain engagement and control of a broad range of clots with minimal compression during removal. The device was cleared by the U.S. Food and Drug Administration (FDA) earlier in 2018 and has been available in Europe since 2016.

While advances in thrombectomy have made it standard practice, about 20 percent or more of ischemic stroke cases remain resistant to the procedure due to the nature and the composition of certain blood clots.[1] In an effort to fill this clinical need, Cerenovus has developed the GCE Revascularization Device, a novel stroke technology shown to retrieve various thrombus types, whether fibrin-rich thrombus (hard) or RBC-rich thrombus (soft). The company received CE mark approval in the European Union for the device in December and is conducting a controlled evaluation study prior to its commercial launch to assess its clinical utility and potential advantages over existing technologies.

Strokes strike nearly 800,000 Americans each year, and is a leading cause of disability, and the fifth leading cause of death.[2] For stroke patients, the difference between life and death, and between functional independence and disability, is tied to timely restoration of blood flow to the oxygen-starved brain after a stroke event occurs.[3] In the U.S. alone, the economic burden of stroke is estimated at $34 billion annually, which includes the cost of health care services, medications, and lost productivity.[4]

For more information: www.cerenovus.com

References

[1] Fennell VS, et al. J NeuroIntervent Surg 2018;0:1–4. doi:10.1136/neurintsurg-2017-013507

[2] American Heart Association "Impact of Stroke (Stroke Statistics)" http://www.strokeassociation.org/STROKEORG/AboutStroke/Impact-of-Stroke-Stroke-statistics_UCM_310728_Article.jsp#.WmDsuSOZMQ8 Date Accessed: 03 December 2018.  

[3] Mayo Foundation for Medical Education and Research (MFMER) "Stroke" https://www.mayoclinic.org/diseases-conditions/stroke/diagnosis-treatment/drc-20350119 Date Accessed: 04 December 2018.

[4] Centers for Disease Control "Stroke Fact Sheet" https://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_stroke.htm Date Accessed: 03 December 2018.

Related Content

FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
Overlay Init